Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
29 July 2021Website:
http://www.rallybio.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 28 Jun 2024 21:14:51 GMTDividend
Analysts recommendations
Institutional Ownership
RLYB Latest News
RallyBio (RLYB) surges by 83% following the announcement of a partnership with J&J to create new treatments aimed at lowering the risk of FNAIT in expectant mothers, accompanied by a $6.6 million investment from J&J.
Rallybio stock is surging today after revealing a partnership with Johnson & Johnson. Johnson & Johnson is providing backing for Rallybio's FNAIT therapy development.
Rallybio has proof of concept data from two more assets, RLYB211 and RLYB116, in addition to their lead asset RLYB212. RLYB212 demonstrated rapid and complete elimination of transfused platelets in patients, while RLYB116 showed a reduction in Free C5 greater than 99%. The company has a cash balance of $138mn and a cash runway of approximately 6 quarters.
The mean of analysts' price targets for Rallybio Corporation (RLYB) points to a 202.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
What type of business is Rallybio?
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
What sector is Rallybio in?
Rallybio is in the Healthcare sector
What industry is Rallybio in?
Rallybio is in the Biotechnology industry
What country is Rallybio from?
Rallybio is headquartered in United States
When did Rallybio go public?
Rallybio initial public offering (IPO) was on 29 July 2021
What is Rallybio website?
https://www.rallybio.com
Is Rallybio in the S&P 500?
No, Rallybio is not included in the S&P 500 index
Is Rallybio in the NASDAQ 100?
No, Rallybio is not included in the NASDAQ 100 index
Is Rallybio in the Dow Jones?
No, Rallybio is not included in the Dow Jones index
When does Rallybio report earnings?
The next expected earnings date for Rallybio is 08 August 2024